The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group receiving only supportive care. Rash was seen in 255 of the patients treated with cetuximab.

Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and ...

Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC. The EGFR pathway has an ...

Common adverse reactions include rash, nausea, diarrhea ... The FDA’s approval of Krazati plus cetuximab offers new hope for colorectal cancer patients with limited treatment options.

The low response rates to existing standard treatments, such as pembrolizumab and cetuximab (20% and 15%-20% respectively), highlight the significant challenge NT219 faces in demonstrating ...